HLX 301
Alternative Names: anti-PDL1 and anti-TIGIT bispecific antibody; HLX-301; TIGIT×PDL1 BispecificLatest Information Update: 21 Jul 2022
Price :
$50 *
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 20 Jun 2022 Phase-I/II clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05390528)
- 20 Jun 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05390528)
- 31 May 2022 Shanghai Henlius Biotech plans a phase I/II trial for Solid tumours or Lymphoma(Late stage disease, Metastatic, Second line treatment or greater) (IV) in June 2022 (NCT05390528).